 |
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/1058445
Czech Republic Pharmaceuticals and Healthcare Report Q3 2009
|
Description: |
The Czech Republic Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on the Czech Republic's pharmaceuticals and healthcare industry.
The Czech pharmaceutical market is among the most developed in Central and Eastern Europe (CEE). Harmonised regulations, high per-capita spending and strong growth have attracted pharmaceutical companies of both research and generic orientation to establish a significant presence in the country.
Through to 2013 the author forecasts a solid, if unspectacular compound annual growth rate (CAGR) for pharmaceutical expenditure of 5.4%.
The Czech Republic is ranked second in the Business Environment Rankings for Q309. Above average scores in all sub-categories reinforces the country’s status as a developed and attractive market.
However, the author believes that the Czech Republic’s regulatory environment is becoming increasingly unattractive to innovative pharmaceutical companies. New rules implemented by the Ministry of Health will require doctors to prescribe drugs by active substance, rather than brand, with pharmacists then dispensing the cheapest version of a medicine.
The Czech Republic was present on the Pharmaceutical Research and Manufacturers of America (PhRMA)’s Special 301 Submission 2009 owing to a negative pricing and reimbursement regime, which constitutes a ‘significant barrier to imported innovative pharmaceuticals’ – likely a result of the negative impact of the country’s jumbo reference pricing groups. The report also criticises restrictive prescription limitations and closely monitored physician drug budgets.
The implementation of healthcare fees for patients saved the Czech health system over CZK10bn (US$498mn) during 2008, according to data from the Ministry of Health. Approximately half of this figure was achieved through fee collection, and the rest through associated cost savings. Meanwhile the single biggest combined savings indicator was pharmacy prescription behaviour, which through the collection of a CZK30 (US$1.48) fee per prescription and a reduction in unnecessary dispensing of medicines is estimated to have cut expenditure by CZK6.07bn (US$0.30bn).
The debacle over the validity and enforcement of prescription fees is a major challenge for pharmacies. In H109 the termination of healthcare fees in certain regions resulted in income figures declining by 30-70% for pharmacies in regions where fees still applied. As a result, private pharmacies had to reduce their operating hours and were forced into staff cutbacks in order to offset the deteriorating financial figures. |
|
Contents: |
Executive Summary
SWOT Analysis
Czech Republic Pharmaceuticals And Healthcare Industry SWOT
Czech Republic Political SWOT
Czech Republic Economic SWOT
Czech Republic Business Environment SWOT
Pharmaceutical Business Environment Ratings
Table: Czech Republic Pharmaceutical Business Environment Ratings
Limits To Potential Returns
Risks to Realisation of Returns
Market Summary
Regulatory Regime
Intellectual Property Environment
Pricing And Reimbursement Issues
Prescribing Rules
Distance Selling
Healthcare Sector
Hospital Sector
Opposition to Health Fees
Industry Forecast Scenario
Overall Market Forecast
Table: Czech Republic’s Drug Market Forecast Indicators, 2004-2013
Key Growth Factors – Industry
Table: Czech Republic’s Health Expenditure Indicators, 2006-2013
Macroeconomic Outlook
Table: Czech Republic - Economic Activity, 2006-2013
Prescription Drug Market Forecast
Table: Czech Republic – Prescription Market Indicators, 2004-2013 (US$mn unless otherwise indicated)
Patented Product Market Forecast
Table: Patented Drugs Market Indicators, 2004-2013
Generic Drug Market Forecasts
Table: Czech Republic’s Generics Market Forecast 2004-2013
OTC Medicine Market Forecast
Table: OTC Drugs Market Indicators, 2004-2013 (US$mn unless otherwise stated)
Medical Device Market Forecast
Czech Republic Medical Device Market Forecast
Pharmaceutical Trade Forecasts
Table: Czech Republic’s Pharmaceutical Trade Indicators, 2004-2013 (US$mn)
Other Healthcare Data Forecasts
Table: Socio-Demographic Indicators, 2004-2013
Key Risks to our Forecast Scenario
Competitive Landscape
Recent Company Developments
Research And Development Sector
Wholesale
Retail Sector
Company Monitor
Multinational Companies
AstraZeneca
Bristol-Myers Squibb
Sanofi-Aventis
Local Companies
Walmark
Zentiva (incorporating Sicomed)
Country Snapshot: Czech Republic Demographic Data
Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
Table: Education, 2002-2005
Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
Table: Employment Indicators, 2001-2006
Table: Consumer Expenditure, 2000-2012 (US$)
Table: Average Annual Wages, 2000-2012
Our Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources |
|
Companies Mentioned |
AstraZeneca, Bristol-Myers Squibb, Sanofi-Aventis, Walmark and Zentiva (incorporating Sicomed) |
|
Ordering: |
Order Online - visit http://www.researchandmarkets.com/reports/1058445
Order by Fax - using the order form below
Order By Post - print the order form below and send to
|
|
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
 |
Page 1 of 2
Printed 28/11/2009 00:07:30 |
|
Fax Order Form
To place an order via fax simply print this form, fill in the information below and
fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net
Order information
Please verify that the product information is correct and select the format you require.
|
|
|
|
Product Name: |
Czech Republic Pharmaceuticals and Healthcare Report Q3 2009
|
|
Web Address: |
http://www.researchandmarkets.com/reports/1058445
|
|
Office Code: |
|
OC8HJNPOUMUXU
|
Report formats
Please enter the quantity of the report format you require.
|
|
Format
|
Quantity
|
Price
|
|
Electronic (PDF)
- Single User
|
|
€440.00
|
Contact information
Please enter all the information below in BLOCK CAPITALS.
|
|
|
First Name: |
Last Name: |
|
Email Address: |
|
|
Job Title: |
|
|
Organisation: |
|
|
Address: |
|
|
City: |
|
|
Postal/Zip Code: |
|
|
Country: |
|
|
Phone Number: |
|
|
Fax Number: |
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
|
|
Page 2 of 2
Printed 28/11/2009 00:07:30
|
|
Payment information
Please indicate the payment method you would like to use by selecting the appropriate
box.
|
|
|
|
|
American Express
|
|
|
Diners Club
|
|
|
Master Card
|
|
|
Visa
|
|
|
|
|
|
|
Cardholder's Name: |
|
|
|
|
Cardholder's Signature: |
|
|
|
|
Expiry Date: |
/ |
|
|
|
Card Number: |
|
|
|
|
CVV Security Code: |
|
|
|
|
Issue Date: |
/ (Diners
Club only)
|
|
|
|
|
|
|
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
|
|
|
|
Please transfer funds to:
|
|
|
Account number: |
83313083 |
|
Sort code: |
98-53-30 |
|
Swift code: |
ULSBIE2D |
|
IBAN number: |
IE78ULSB98533083313083 |
|
Bank Address: |
Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland. |
|
|
|
If you have a Marketing Code please enter it below:
|
|
|
Marketing Code: |
|
|
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
|
|
|
|
|
|
